Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in KIT-mutated refractory metastatic cancer
NCT02461849Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Apr 2014
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in solid tumor, sponsored by Samsung Medical Center. Primary endpoint: Response Rate at 24 weeks. Status: unknown.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02461849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02461849.